MedTrace Logo

Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression

NCT00621751 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2022-04-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if carbamazepine reduces irritability and aggression among individuals with traumatic brain injury

Conditions

Interventions

DRUG

Carbamazepine

800 mg daily

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • U.S. Department of Education

    collaborator FED

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Flora M Hammond, MD · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2013-09-30
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00621751 on ClinicalTrials.gov